11/10/2018 - 15:32

MGC gains tick of approval cannabis epilepsy drug

11/10/2018 - 15:32

Bookmark

Save articles for future reference.

MGC Pharmaceuticals has reached a major milestone after receiving formal authorisation to sell its CannEpil medical cannabis based epilepsy treatment in Australia through specialist prescribers under the Authorised Prescriber Scheme. This signals the start of commercial-scale production of CannEpil at MGC’s EU GMP certified facility in Slovenia. CannEpil is expected to generate $1m in annualised revenues from an initial base of about 100 patients.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options